Jun 08, 2023 / 08:00PM GMT
Kelly Shi - Jefferies - Analyst
(inaudible) everyone. Thank you for attending Jefferies' New York Healthcare Conference. My name is Kelly Shi, one of the Biotech Analyst here. And please join me to welcome, Dr. Tim Bertram, Chief Executive Officer of ProKidney for this fireside chat session. And then we're going to talk about the novel cell therapy and with the big potential for treating CKD space. And welcome, Tim.
Questions and Answers:
Kelly Shi - Jefferies - AnalystMaybe first, you can talk about the company overview to the audience who are not so familiar with your story.
Tim Bertram - ProKidney Corp. - CEO & Director
Yeah, thank you, Kelly, and thank you all of you for -- to hear our story. ProKidney is an autologous homologous cell therapy company with a mission and goal to end kidney failure. This is important on a number of levels because part of our mission and goal also is to drive down cost for both the patient and the healthcare system.
We're in Phase 3 clinical stage pharmaceutical
Trustpilot
